Release Date: April 20, 2021
Expiration Date: April 20, 2022
The joint-providership will target an audience consisting of gastroenterologists, nurse practitioners (NPs), physician assistants (PAs), and nurses.
The series will focus on emerging treatment updates and review current treatment guidelines.
Upon completion of this educational activity, participants should be able to:
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Purdue University College of Pharmacy and IBD ReMEdY. Purdue University College of Pharmacy, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians.
Purdue University College of Pharmacy designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
All faculty, staff and reviewers involved in the planning, review or presentation of continuing education activities provided by Purdue University College of Pharmacy are required to disclose to the audience any relevant commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity.
All additional planning committee members, staff and reviewers of IBD ReMEdY and Purdue University College of Pharmacy have no relationships to disclose.
Americans with Disabilities Act:
The event staff will be glad to assist you with any special needs (i.e., physical, dietary). Please contact us prior to the event at 1-888-565-5321.
This program is supported by educational grants from AbbVie, Bristol-Myers Squibb, Janssen Biotech, Inc., and Takeda Pharmaceuticals U.S.A., Inc.